Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)

Autologous stem cell transplantation for patients aged 60 years or older with refractory or relapsed classical Hodgkin’s lymphoma: a retrospective analysis from the French Society of Bone Marrow Transplantation and Cell Therapies (SFGM-TC)

This report retrospectively analyzed the outcome of 91 patients aged 60 years or older with refractory/relapsed (R/R) classical Hodgkin's lymphoma (cHL) who underwent autologous stem cell transplantation (ASCT) between 1992 and 2013 and were reported to the French Society of Bone Marrow Transpl...

Full description

Saved in:
Bibliographic Details
Published in:Bone marrow transplantation (Basingstoke) Vol. 51; no. 7; pp. 928 - 932
Main Authors: Stamatoullas, A, Brice, P, Gueye, M S, Mareschal, S, Chevallier, P, Bouabdallah, R, Nguyenquoc, S, Francois, S, Turlure, P, Ceballos, P, Monjanel, H, Bourhis, J-H, Guillerm, G, Mohty, M, Biron, P, Cornillon, J, Belhadj, K, Bonmati, C, Dilhuydy, M-S, Huynh, A, Bernard, M, Chrétien, M-L, Peffault de Latour, R, Tilly, H
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 01-07-2016
Nature Publishing Group
Subjects:
692/699/1541/1990
692/699/1541/1990/291
692/699/1541/1990/291/1556
Age Factors
Aged
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Autografts
Bone marrow
Bone marrow transplantation
Care and treatment
Cell Biology
Cell therapy
Chemotherapy
Cytarabine
Elderly patients
Etoposide
Evaluation
Female
Follow-Up Studies
Hematology
Hematopoietic Stem Cell Transplantation - adverse effects
Hematopoietic Stem Cell Transplantation - methods
Hematopoietic Stem Cell Transplantation - mortality
Hodgkin Disease - mortality
Hodgkin Disease - therapy
Hodgkin's disease
Hodgkin's lymphoma
Humans
Internal Medicine
Lymphoma
Male
Medical prognosis
Medicine
Medicine & Public Health
Melphalan
Methods
Middle Aged
Missing data
original-article
Patient outcomes
Patients
Physiological aspects
Positron emission
Positron emission tomography
Practice guidelines (Medicine)
Public Health
Retrospective Studies
Salvage Therapy - methods
Salvage Therapy - mortality
Stem cell transplantation
Stem Cells
Survival
Survival Analysis
Tomography
Toxicity
Transplantation
Transplantation, Autologous
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:This report retrospectively analyzed the outcome of 91 patients aged 60 years or older with refractory/relapsed (R/R) classical Hodgkin's lymphoma (cHL) who underwent autologous stem cell transplantation (ASCT) between 1992 and 2013 and were reported to the French Society of Bone Marrow Transplantation and Cell Therapies registry. The median age at transplant was 63 years. The majority of patients exhibited disease chemosensitivity to salvage treatment (57 complete responses, 30 partial responses, 1 progressive disease and 3 unknown). The most frequent conditioning regimen consisted of BCNU, cytarabine, etoposide, melphalan (BEAM) chemotherapy (93%). With a median follow-up of 54 months, 5-year estimates of overall survival (OS) and progression free survival (PFS) for the entire group were 67 and 54%, respectively. Despite the missing data, in univariate analysis, the number of salvage chemotherapy lines (1–2 versus ⩾3) significantly influenced the OS, unlike the other prognostic factors (stage III–IV at relapse, disease status before ASCT and negative positron emission tomography (PET) scan) encountered in younger patients. In spite of its limitations, this retrospective study with a long-term follow-up suggests that ASCT is a valid treatment option for chemosensitive R/R cHL in selected elderly patients, with an acceptable rate of toxicity.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0268-3369
1476-5365
DOI:10.1038/bmt.2016.76